Biotech & CGT

Industry introduction

The biotech industry has shown great performance and growth during an unprecedented time of global disruption; however, many long term issues have not yet been resolved. Many new therapies consist of highly sensitive and, more often than not, patient-specific material that require special processing and handling, impacting all aspects of the value chain. Companies have to make decisions based on risk and reward, and successfully bringing these advanced therapies to market – and to the patient – requires careful planning and consideration early on.

The main challenges we see for biotech, CGT and advanced therapy supply chains

Sterile Modern Factory: Professionals in Coveralls, Masks Working on CNC Machinery. Medical Electronics Manufacturing Laboratory with High Tech Robot Arm Production Line and Contemporary Equipment

New ways of planning

Building a responsive and flexible supply chain is key for these specialized treatments with often very short product shelf life.

Patient populations are limited and treatments are often one-time only.

Planning manufacturing slots internally or at CDMOs requires an extra layer of coordination, including healthcare professionals and patient intake at treatment centers.

Two fully equipped coworkers in protective workwear seen in a pharmaceutical laboratory

Changing manufacturing models

Traditional pharmaceutical supply chains rely on centralized manufacturing.

New therapy value chains operate much closer to the patient, driving a re-evaluation of existing operating models.

Conveyor belt worker operates a robot that transports insulin bags - modern factory for the production of medicines in the healthcare sector

Ramp-up and scaling

When moving from Phase I/II to Phase III trials and commercialization, one of the biggest challenges is to ramp-up to commercial scale production.

This impacts all processes, functions and systems.

Shot of a pharmacist looking for an ordered drug on a shelf at the local pharmacy.

Specialized fulfillment

Biotech and CGT companies require highly specialized logistics partners that can handle sensitive materials under strict time constraints.

Integrating these partners is often a bottleneck and can have dramatic consequences.

Research Scientist Takes Out Petri Dish with Samples from Opened Refrigerator Box.

Cold chain management

To be successful, sound cold chain management processes are required for product efficacy, product safety, and adherence to relevant regulatory or patient requirements.

Today, companies are competing every day more and more for capacity in an already constrained market.

How we help the biotech & CGT industry

  • CGT operations planning and scheduling (Binocs)

    Our Binocs SaaS solution is used by many CGT companies to execute their CGT patient journey in real-time. Scheduling patient journeys with confidence, resolving resource conflicts, and orchestrating the entire CGT supply chain to deliver life-saving therapies to more patients.

    Learn more
  • Smart planning optimization

    Our business consulting teams help to introduce new planning concepts that complement traditional pharma supply chain planning, focused specifically on advanced therapies.

    Learn more
  • Supply chain systems

    Our business and technology experts work together with many biotech companies who are in the midst of commercialization to implement the new supply chain systems and capabilities that are required to support new product launches.

    Learn more
  • Cold chain management

    Working closely together with specialist logistics providers and other relevant distribution partners, we help companies to set up the fresh/frozen cold chain models they need to ensure product conditions are kept within optimal ranges.

    Learn more
  • Patient-specific supply chains

    Operating a supply chain to deliver patient-specific treatments is substantially different from traditional (pharmaceutical) supply chains. We help to build the patient-specific supply chains of the future.

    Learn more